Home›Stocks›ORMP

ORMP — structural market context

Oramed Pharmaceuticals Inc. Co

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 21. Each line shows the earlier value, the later value and their dates.

Price

Close $4.14 (Oct 21) vs $4.15 (Oct 20): −0.24%.

Volume

0.56× its 20-session average (151K) on Oct 21.

Includes pre- and post-market trading.

Short interest

Short interest 1.4M shares (settlement Sep 30) vs 1.3M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 5 days with fails, largest 1K shares on Sep 24.

Previous file (settlements Sep 1–Sep 14, published Sep 30): no fails listed.

No new publication in this window.

Insider filings (Form 4)

None recorded in this window.

ORMP events and their magnitude

Latest SEC filing in the event study

Form 4 · sale · filed 2026-10-02 · View on sec.gov ↗

…

Open the Event Study →

ORMP short interest & days to cover

SHARES SHORT
1.4M
% OF FLOAT
4.6%
DAYS TO COVER
7.3
CHANGE VS PRIOR
+9.6%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (22d ago)

ORMP fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-25 · 27d2$4.79
2026-09-24 · 28d1K$4.72
2026-09-21 · 31d685$4.74

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

ORMP insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 2 sales

InsiderTypeSharesValueFiled
Gabay Avraham · officer: Chief Financial OfficerSale (S)20K$90K2026-10-02
Hexter Joshua · officer: COO & CBOSale (S)30K$135K2026-10-02

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

Frequently asked questions

What is ORMP's short interest?
As of the FINRA settlement date 2026-09-30, ORMP had 1.4M shares sold short — 4.6% of its float, with 7.3 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying ORMP?
In the last 12 months of SEC Form 4 filings, ORMP recorded 0 insider purchases and 2 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
Is this page telling me to buy or sell ORMP?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with O

OXY · Occidental Petroleum CorporatiODC · Oil-Dri Corporation ofOGC · OceanaGold CorporationOKE · Oneok, Inc.OMF · OneMain Holdings, Inc.ONC · BeOne Medicines Ltd.All O →

ORMP: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.